The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "adalimumab"

Search results for: adalimumab

Oxford University to Study Adalimumab as Potential COVID-19 Treatment

September 30, 2020 • By Josephine Mason & Kate Kelland

LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown… [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, COVID-19

FDA Approves the Biosimilar Hadlima (Adalimumab-bwwd)

September 16, 2019 • By Michele B. Kaufman, PharmD, BCGP

Hadlima (adalimumab-bwwd), which is biosimilar to adalimumab, is now FDA approved to treat multiple autoimmune diseases…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab-bwwd, FDA, FDA approval, Hadlima, U.S. Food and Drug Administration (FDA)

Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up

July 10, 2019 • By Lara C. Pullen, PhD

A five-year study in patients with juvenile idiopathic arthritis-associated uveitis found drug-induced disease remission did not persist once adalimumab was stopped after long-term treatment.... [Read More]

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: adalimumab, JIA, juvenile idiopathic arthritis (JIA), Uveitis

Ixekizumab vs. Adalimumab for PsA: How Do They Compare?

July 1, 2019 • By Michele B. Kaufman, PharmD, BCGP

In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, EULAR, ixekizumab, psoriatic arthritis

The Rescue: Moving RA Patients from Adalimumab to Baricitinib

June 25, 2019 • By Lara C. Pullen, PhD

The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…... [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: adalimumab, baricitinib, Rheumatoid Arthritis (RA), washout

Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

April 3, 2019 • By Michele B. Kaufman, PharmD, BCGP

Health Canada has approved adalimumab for treating chronic non-infectious anterior uveitis in patients 2 years and older…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, non-infectious anterior uveitis, Pediatric, Uveitis

Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA

January 14, 2019 • By Michele B. Kaufman, PharmD, BCGP

In a recent study, ixekizumab proved safe and effective in treating adults with psoriatic arthritis (PsA) and plaque psoriasis compared with adalimumab…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, ixekizumab, PsA, psoriatic arthritis

Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

October 22, 2018 • By Michele B. Kaufman, PharmD, BCGP

According to new data, BMS-986165, an oral, selective tyrosine kinase 2 inhibitor, may be safe and effective for treating plaque psoriasis…... [Read More]

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, adalimumab-adbm, BMS-986165, plaque psoriasis, TYK2 inhibitor, tyrosine kinase 2 inhibitor

Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis

August 20, 2018 • By Lorraine L. Janeczko

NEW YORK (Reuters Health)—In patients with active non-radiographic axial spondyloarthritis (nr-axSpA) who achieved remission while taking adalimumab, researchers saw fewer flares among those who continued taking the drug than among those who stopped taking it. “The results showed that continued therapy with adalimumab was associated with a higher rate of maintenance of remission compared with… [Read More]

Filed Under: Conditions, Spondyloarthritis Tagged With: adalimumab, axial spondyloarthritis (SpA), non-radiographic axial spondyloarthritis, Remission

Adalimumab Appears Safe for Treating Pediatric Patients with Autoimmune Disease

August 8, 2018 • By Reuters Staff

NEW YORK (Reuters Health)—Adalimumab appears to be safe for treating pediatric patients with polyarticular juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), psoriasis and Crohn’s disease (CD), according to data from company-sponsored clinical trials. Adalimumab is an anti-tumor necrosis factor monoclonal antibody with demonstrated efficacy in these conditions, but pediatric safety data remains limited. Dr. Gerd… [Read More]

Filed Under: Conditions, Drug Updates Tagged With: adalimumab, Crohn's disease (CD), enthesitis-related arthritis (ERA), polyarticular juvenile idiopathic arthritis (JIA), Psoriasis

  • 1
  • 2
  • 3
  • …
  • 28
  • Next Page »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.